Amphetamine Drugs Market Share

North America Market Insights

The North America market is expected to hold the largest market share of 49% during the forecast period, driven by the presence of an effective support system from the government, high R&D activities, and a well-established healthcare facility. Federal organizations such as the NIH and CDC are actively sponsoring research and awareness campaigns for ADHD, leading to growing levels of diagnosis and treatment. The FDA has expedited approval for branded and generic amphetamine versions, and the DEA is in discussions with producers to end stimulant shortages by adjusting production quotas. Domestic manufacturing capacity is increasing, including FDA-approved plants producing amphetamine mixed salts, which provides an assured supply chain.

The amphetamine drugs market in the U.S. is growing due to government initiatives and research and development efforts. According to a report by the CDC in February 2024, in 2022, nearly 6 children out of 10 were reported to have had moderate or severe ADHD in the U.S. R&D will witness build-up in formulation research and development for amphetamine type drugs with an emphasis on extended release, top patient preference and doctor demand. At the same time, the United States Food and Drug Administration has enforced changes in approval processes for generic amphetamines, inducing competition and aiding gross market growth in amphetamine drug market.

The amphetamine drugs market in Canada is growing due to government programs such as the Scientific Research and Experimental Development (SR&ED) Tax Credit Program, which offers financing to firms that engage in research and development within the pharmaceutical industry. As per a report by CDA in November 2024, ADHD is a neurodevelopmental and neurologic disorder, which exists in 4% to 6% adults and 5% to 7% of children in Canada, therefore encouraging the amphetamine drug market. In addition, the federal government has been investing in healthcare infrastructure, expanding mental healthcare access, including treatment for such diseases as ADHD, which typically involves amphetamine medication.

Exporters and Importers of Pharmaceutical Products in 2023

Source: OEC, September 2025

Asia Pacific Market Insights

The amphetamine drugs market in the Asia Pacific is expected to hold the fastest-growing market within the forecast period due to several key factors. Governments in the region are stepping up efforts to curb the increasing prevalence of certain amphetamine-type stimulants. According to the United Nations Office on Drugs and Crime (UNODC), a major increase in methamphetamine seizures has occurred in South Asia, signaling that the synthetic drug trafficking menace is getting worse. Also, pricing strategies are purportedly getting affected in the region, considering that governments have taken up policies directed toward making the medicines more affordable and accessible to the masses that can increase the amphetamine drug market.

The amphetamine drugs market in China is growing as governments begin to regulate and criminalize the production of amphetamines, as well as with the emergence of pharmaceutical R&D efforts for better formulations. As per a report by NLM in July 2025, 42.2% of 12,376 children surveyed reported ADHD-related symptoms. In addition, China has been making efforts to improve healthcare infrastructure and accessibility, assisting in further adoption of diagnosis and treatment. Greater awareness and acceptance of mental health concerns are also behind the growing demand for amphetamine-based therapies in the country.

The amphetamine drugs market in India is growing due to increasing awareness of ADHD and associated healthcare infrastructure enhancement, and governmental supportive policies to increase mental health services all play their part. Governmental bodies such as the National Narcotics Control Bureau (NCB) also strive to clamp down on illegal production and trafficking of amphetamines and remain helpful through a stable legal supply. As per a report by UNICEF in September 2025, by 2022, the prevalence had increased nearly fivefold among children aged 5 to 9, 10 to 14, and 15 to 19 years. It is going to be enhanced to meet the growing domestic demands, both from public and private investment programs.

Europe Market Insights

The amphetamine drugs market in Europe is expected to grow steadily within the forecast period due to increasing demand for stimulant-based treatments, chiefly for attention-deficit/hyperactivity disorder (ADHD). Governments all over Europe are trying to enhance mental health services and create better access for diagnosis and treatment, jointly supporting the R&D of pharmaceutical formulations. Manufacturing capacities are being ramped up to meet the increasing demand for highly-quality amphetamine-based drugs. As per a report by the World Health Organization in 2022, 60% of adults and one in three children are obese in Europe, which increases the market.

The amphetamine drugs market in the UK is growing due to a steadily increasing diagnosis of adults with Attention-Deficit/Hyperactivity Disorder (ADHD). However, as per a report by ADDA in 2025, only about 1 in 9 UK adults with the condition have received a formal diagnosis, implying huge treatment and assessment gaps, signifying serious underdiagnosis, and unmet treatment needs. This gap has led to a surge in demand for diagnosis and medication, with prescriptions under the NHS for amphetamine and related stimulant drugs mushrooming sevenfold in the last ten years. 

The amphetamine drugs market in Germany has been growing with an increase in recognition of ADHD in children and adults and with expansion in treatment options, most importantly, approval for adult use in Germany of lisdexamfetamine (Vyvanse) as of 2024, following the European trend to broaden indications for treatment. The approval of lisdexamfetamine (Vyvanse) for adult use in 2024 shows a major milestone in shifting and broadening the focus of treatment of adults. The healthcare authorities in Germany have also made improvements in reimbursement schemes and clinical guidelines to enable greater accessibility of stimulant medications through statutory health insurance.